From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Yellow nail syndrome lung exacerbations should be treated with a comprehensive approach, including antibiotics, supplemental oxygen, bronchodilators, and management of underlying lymphatic abnormalities, with the goal of reducing morbidity, mortality, and improving quality of life. The treatment of yellow nail syndrome (YNS) is primarily symptomatic and supportive, as the etiology remains unknown 1. The syndrome is characterized by a triad of yellow nail discoloration, pulmonary manifestations, and lower limb lymphedema, with chronic sinusitis frequently associated with the triad 1.
Key Considerations
- Antibiotics targeting common respiratory pathogens, such as fluoroquinolones or amoxicillin-clavulanate, may be used to treat lung exacerbations [@Example@].
- Supplemental oxygen, bronchodilators like albuterol, and chest physiotherapy can help manage symptoms during acute exacerbations [@Example@].
- Oral corticosteroids, such as prednisone, may be used to reduce inflammation [@Example@].
- Long-term management includes prophylactic antibiotics, regular vaccinations against influenza and pneumococcus, and monitoring with pulmonary function tests and chest imaging [@Example@].
Recent Evidence
A recent review of YNS highlights the importance of symptomatic treatment and the potential for spontaneous resolution of symptoms 2. Another study suggests that oral vitamin E, alone or in combination with triazole antifungals, may improve nail discoloration, and pleural effusion can be treated surgically or with pleurodesis 1.
Treatment Approach
The most recent and highest quality study 3 suggests that a comprehensive approach to treatment, including management of pleural effusions, lymphedema, and respiratory symptoms, is essential for improving patient outcomes. This approach should prioritize reducing morbidity, mortality, and improving quality of life, and may involve a combination of medical and surgical interventions.